Pipeline

Advancing the CAR 2.0 Therapy Through the Clinical Trial Milestones

SynKIR™ has shown significant promise in in-vivo solid tumor models. The lead pipeline is currently under investigation in the First-in-Human Phase 1 Clinical Trial.